Terms: = Lymphoma AND EIF4A2, DDX2B, 1974, ENSG00000156976, EIF4F, BM-010, EIF4A
465 results:
1. COVID-19 and non-Hodgkin's lymphoma: A common susceptibility pattern?
Sara M; Minelli C; Broccia G; Vineis P; Cocco P
PLoS One; 2023; 18(3):e0277588. PubMed ID: 36928185
[TBL] [Abstract] [Full Text] [Related]
2. Malignant Neoplasms of the Gastrointestinal Tract After Blood or Marrow Transplant.
McDonald A; Dai C; Meng Q; Hageman L; Richman J; Wu J; Francisco L; Ross E; Balas N; Bosworth A; Te HS; Wong FL; Landier W; Salzman D; Bhatia R; Weisdorf DJ; Forman SJ; Armenian SH; Bhatia S
JAMA Oncol; 2023 Mar; 9(3):376-385. PubMed ID: 36656600
[TBL] [Abstract] [Full Text] [Related]
3. Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation.
Thus YJ; De Rooij MFM; Swier N; Beijersbergen RL; Guikema JEJ; Kersten MJ; Eldering E; Pals ST; Kater AP; Spaargaren M
Haematologica; 2023 Mar; 108(3):797-810. PubMed ID: 36226498
[TBL] [Abstract] [Full Text] [Related]
4. Novel eif4a1 inhibitors with anti-tumor activity in lymphoma.
Kayastha F; Herrington NB; Kapadia B; Roychowdhury A; Nanaji N; Kellogg GE; Gartenhaus RB
Mol Med; 2022 Sep; 28(1):101. PubMed ID: 36058921
[TBL] [Abstract] [Full Text] [Related]
5. B-cell receptor signaling induces proteasomal degradation of PDCD4 via MEK1/2 and mTORC1 in malignant B cells.
Taylor J; Wilmore S; Marriot S; Rogers-Broadway KR; Fell R; Minton AR; Branch T; Ashton-Key M; Coldwell M; Stevenson FK; Forconi F; Steele AJ; Packham G; Yeomans A
Cell Signal; 2022 Jun; 94():110311. PubMed ID: 35306137
[TBL] [Abstract] [Full Text] [Related]
6. Incidence of non-Hodgkin's lymphoma among adults in Sardinia, Italy.
Broccia G; Carter J; Ozsin-Ozler C; Meloni F; De Matteis S; Cocco P
PLoS One; 2022; 17(2):e0260078. PubMed ID: 35108286
[TBL] [Abstract] [Full Text] [Related]
7. Discovery of an eif4a Inhibitor with a Novel Mechanism of Action.
Zerio CJ; Cunningham TA; Tulino AS; Alimusa EA; Buckley TM; Moore KT; Dodson M; Wilson NC; Ambrose AJ; Shi T; Sivinski J; Essegian DJ; Zhang DD; Schürer SC; Schatz JH; Chapman E
J Med Chem; 2021 Nov; 64(21):15727-15746. PubMed ID: 34676755
[TBL] [Abstract] [Full Text] [Related]
8. Prognostic nutritional index, a novel biomarker which predicts worse prognosis in diffuse large B cell lymphoma.
He J; Yin H; Xia Y; Wu JZ; Liang JH; Zhu HY; Fan L; Li JY; Wang L; Xu W
Leuk Res; 2021 Nov; 110():106664. PubMed ID: 34271293
[TBL] [Abstract] [Full Text] [Related]
9. Inhibition of translation initiation factor eif4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML.
Nishida Y; Zhao R; Heese LE; Akiyama H; Patel S; Jaeger AM; Jacamo RO; Kojima K; Ma MCJ; Ruvolo VR; Chachad D; Devine W; Lindquist S; Davis RE; Porco JA; Whitesell L; Andreeff M; Ishizawa J
Leukemia; 2021 Sep; 35(9):2469-2481. PubMed ID: 34127794
[TBL] [Abstract] [Full Text] [Related]
10. Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia.
Jain N; Maiti A; Ravandi F; Konopleva M; Daver N; Kadia T; Pemmaraju N; Short N; Kebriaei P; Ning J; Cortes J; Jabbour E; Kantarjian H
Am J Hematol; 2021 Aug; 96(8):1000-1007. PubMed ID: 33991360
[TBL] [Abstract] [Full Text] [Related]
11. Late effects in survivors treated for lymphoma as adolescents and young adults: a population-based analysis.
Lo AC; Chen B; Samuel V; Savage KJ; Freeman C; Goddard K
J Cancer Surviv; 2021 Dec; 15(6):837-846. PubMed ID: 33453004
[TBL] [Abstract] [Full Text] [Related]
12. Targeting eif4f translation initiation complex with SBI-756 sensitises B lymphoma cells to venetoclax.
Herzog LO; Walters B; Buono R; Lee JS; Mallya S; Fung A; Chiu H; Nguyen N; Li B; Pinkerton AB; Jackson MR; Schneider RJ; Ronai ZA; Fruman DA
Br J Cancer; 2021 Mar; 124(6):1098-1109. PubMed ID: 33318657
[TBL] [Abstract] [Full Text] [Related]
13. Parameter perturbations in a post-treatment chronic myeloid leukemia model capture the essence of pre-diagnosis A-bomb survivor mysteries.
Radivoyevitch T
Radiat Environ Biophys; 2021 Mar; 60(1):41-47. PubMed ID: 33125593
[TBL] [Abstract] [Full Text] [Related]
14. Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eif4a.
Thompson PA; Eam B; Young NP; Fish S; Chen J; Barrera M; Howard H; Sung E; Parra A; Staunton J; Chiang GG; Gerson-Gurwitz A; Wegerski CJ; Nevarez A; Clarine J; Sperry S; Xiang A; Nilewski C; Packard GK; Michels T; Tran C; Sprengeler PA; Ernst JT; Reich SH; Webster KR
Mol Cancer Ther; 2021 Jan; 20(1):26-36. PubMed ID: 33037136
[TBL] [Abstract] [Full Text] [Related]
15. Whole-body muscle magnetic resonance imaging in patients with muscle symptoms: incidental findings and outcomes.
Claeys KG; Goosens V
Eur J Neurol; 2021 Jan; 28(1):323-330. PubMed ID: 32892468
[TBL] [Abstract] [Full Text] [Related]
16. Non-infectious Complications of Common Variable Immunodeficiency: Updated Clinical Spectrum, Sequelae, and Insights to Pathogenesis.
Ho HE; Cunningham-Rundles C
Front Immunol; 2020; 11():149. PubMed ID: 32117289
[TBL] [Abstract] [Full Text] [Related]
17. Prohibitin (PHB) expression is associated with aggressiveness in DLBCL and flavagline-mediated inhibition of cytoplasmic PHB functions induces anti-tumor effects.
Bentayeb H; Aitamer M; Petit B; Dubanet L; Elderwish S; Désaubry L; de Gramont A; Raymond E; Olivrie A; Abraham J; Jauberteau MO; Troutaud D
J Exp Clin Cancer Res; 2019 Nov; 38(1):450. PubMed ID: 31684984
[TBL] [Abstract] [Full Text] [Related]
18. Amidino-Rocaglates: A Potent Class of eif4a Inhibitors.
Chu J; Zhang W; Cencic R; Devine WG; Beglov D; Henkel T; Brown LE; Vajda S; Porco JA; Pelletier J
Cell Chem Biol; 2019 Nov; 26(11):1586-1593.e3. PubMed ID: 31519508
[TBL] [Abstract] [Full Text] [Related]
19. As the world turns, evolving lymphoma classifications-past, present and future.
Swerdlow SH; Cook JR
Hum Pathol; 2020 Jan; 95():55-77. PubMed ID: 31493426
[TBL] [Abstract] [Full Text] [Related]
20. Late mortality after bone marrow transplant for chronic myelogenous leukemia in the context of prior tyrosine kinase inhibitor exposure: A Blood or Marrow Transplant Survivor Study (BMTSS) report.
Wu J; Chen Y; Hageman L; Francisco L; Ness EC; Parman M; Kung M; Watson JA; Weisdorf DJ; Snyder DS; McGlave PB; Forman SJ; Arora M; Armenian SH; Bhatia R; Bhatia S
Cancer; 2019 Nov; 125(22):4033-4042. PubMed ID: 31412155
[TBL] [Abstract] [Full Text] [Related]
[Next]
